Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate

Imatinib has shown unprecendeted success in the treatment of chronic myeloid leukemia (CML). However, over few years there have been reports regarding the primary and secondary resistance to Imatinib dampening the overall outcome in CML patients. In this study we have tried to assess the effect of d...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajappa, Senthil, Mallavarapu, Krishna Mohan, Gundeti, Sadashivudu, Paul, Tara Roshni, Jacob, Rachel Thomas, Digumarti, Raghunadharao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902631/
https://www.ncbi.nlm.nih.gov/pubmed/24516316
http://dx.doi.org/10.4103/0971-5851.123750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902631/
https://www.ncbi.nlm.nih.gov/pubmed/24516316
http://dx.doi.org/10.4103/0971-5851.123750

Ejemplares similares